Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2016-08-08 Regulatory Filings
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2016-08-08 English
FORM 25
Delisting Announcement
2016-08-05 English
FORM 10-Q
Interim / Quarterly Report Q1 2017
2016-08-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2016, reporting the issuance of a press release announcing financial results for the first quarter ending June 30, 2016. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is being furnished, not filed, and is not incorporated by reference into other filings. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results. Given the document length is only 2806 characters and it primarily serves to announce the earnings release, this fits the definition of an Earnings Release (ER) announcement. However, since the document is the 8-K filing announcing the earnings release and includes the press release as an exhibit, it is best classified as an Earnings Release (ER) because the press release is included and the document is the initial announcement of quarterly financial results.
2016-08-04 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 31, 2016, reporting the appointment of a new Chief Financial Officer, Craig Kussman. The key section is Item 5.02, which covers departure and appointment of directors or certain officers. The content focuses on management changes, including employment terms and compensation details. There is no financial performance data or earnings information, nor is it a report or announcement of voting results, dividends, or capital changes. The document is not a transcript, audit report, or legal proceeding update. It clearly fits the category of Board/Management Information (MANG) as it announces changes in senior management.
2016-08-02 English
Regulatory Filings 2016
Regulatory Filings
2016-07-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.